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Abstract
Young men who have sex with men (YMSM) face a disproportionately high burden of HIV. Oral 
pre-exposure prophylaxis (PrEP) is effective in preventing HIV acquisition, but adherence to PrEP 
among YMSM may be inadequate. Medication adherence may be assessed via biomarkers, which 
are expensive and invasive, or via self-report through Audio Computer Assisted Self-Interview 
(ACASI), which may result in over-reporting of adherence. In this paper we assess the potential of 
a new method of self-report, the Interactive Questionnaire System (iQS), in validly estimating true 
adherence rates. PrEP adherence among 167 YMSM aged 15 to 23 was measured via dried blood 
spot (DBS), ACASI, and iQS twice over a 24-week study period. Both ACASI- and iQS-reported 
data revealed that over 40% of individuals self-reporting adequate PrEP adherence had DBS-
estimated drug levels indicating inadequate adherence. Adjusted logistic repeated measures 
random intercept regression analyses indicated that younger YMSM had higher odds of over-
reporting adherence than older YMSM – each one year increase in age was associated with 0.79 
times the odds of over-reporting adherence (95% CI:0.63, 0.98; p-value=0.031), and being African 
American was associated with 3.22 times greater odds of over-reporting than non-African 
Americans (95% CI:1.51, 6.90; p-value=0.0003). These results suggest that ACASI and iQS 
methods of self-report significantly overestimate true PrEP adherence rates among YMSM, and 
that the odds of over-reporting adherence may be affected by both age and race.
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INTRODUCTION
Better Human Immunodeficiency Virus (HIV) prevention strategies are urgently needed for 
key populations. While HIV incidence in the United States (U.S.) has remained stable over 
recent years, HIV incidence is increasing among men who have sex with men (MSM), and 
especially among young MSM (YMSM) aged 13 to 24 years (1). Male-to-male sexual 
contact is the primary route for HIV transmission in the U.S., and was responsible for 
29,771 new HIV cases in the U.S. in 2014 (2). Considering that there were 44,073 incident 
cases of HIV in the U.S. overall in 2014, MSM represent over 67% of new HIV infections, 
despite the fact that MSM make up less than 5% of the U.S. population (1–3). YMSM also 
face a disproportionate burden of HIV, with approximately 7,100 infections in this 
population in 2014, and an increasing HIV incidence (2). Black and Latino YMSM faced an 
87% increase in HIV incidence from 2005 to 2014, while white YMSM faced a 56% 
increase in HIV incidence during this period – such drastic increases in HIV incidence have 
seldom been seen in any other population groups in the U.S. (4,5).
Numerous studies have shown pre-exposure prophylaxis (PrEP) to be efficacious in the 
prevention of HIV among MSM in clinical trials (6–9). However, PrEP efficacy is highly 
dependent on medication adherence (10). Although it is prescribed as a once daily oral 
medication, PrEP’s emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) drug 
concentrations may reach adequate levels to confer protection against HIV when taken at 
least four times a week (9). However, previous PrEP trials have shown that adherence rates 
are often low, and thus drug concentrations often fail to reach protective levels in study 
populations (9,11,12). Poor PrEP adherence has been documented in both women and MSM 
(12–14). Recently, two PrEP trials conducted among HIV negative women in sub-Saharan 
Africa were halted due to futility as a result of extremely low adherence levels (12,14). In 
both trials, the adherence rates self-reported via Audio Computer Assisted Self-Interview 
(ACASI) were relatively high, although only about one quarter to one third of plasma 
samples had any FTC/TDF detectable (12). MSM in the placebo-controlled iPrEx trial self-
reported PrEP adherence of over 90% in computer-assisted self-interview (CASI), but 
peripheral blood mononuclear cells (PBMC) indicated that of those in the PrEP treatment 
arm, only 53% of subjects had any FTC/TDF detectable (15). In the iPrEx open-label 
extension (OLE), overall adherence was higher, at 71% (9). Among those who had drug 
measurements during both the iPrEx placebo-controlled trial, and iPrEx-OLE, the proportion 
of those with FTC/TDF detected was higher in iPrEx-OLE (9). It is possible that our study 
may reveal similar PrEP adherence rates as was found in iPrEx-OLE, and greater adherence 
rates than was found in iPrEx, due to the generally higher adherence levels found in open-
label vs. placebo-controlled PrEP studies (16). However, it is probable that participants in 
our study may have lower adherence rates than those enrolled in iPrEx-OLE, given that our 
study population consists of YMSM, a population that may face greater barriers to PrEP 
adherence (13,17). The first study to pilot PrEP among YMSM found large discrepancies 
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between self-reported adherence and detected drug levels in blood, adding to the evidence 
that adherence to PrEP is lower than reported across populations, and adherence self-
reported via ACASI may be invalid (13,18).
Although biomarker data may be considered the “gold-standard” for adherence 
measurement, obtaining biological samples is expensive, invasive, and associated with high 
burdens for patients, researchers, and healthcare workers. ACASI, though potentially less 
biased than face-to-face interviews, may result in over-reporting of behaviors that are 
perceived as positive, and under-reporting of behaviors deemed more negative (19). 
Medication adherence, considered a socially desirable behavior, is thus often over-reported 
when assessed via ACASI self-report in HIV PrEP trials, as reported above (19). To address 
this issue, a new method to report adherence, the Interactive Questionnaire System (iQS), 
was developed to assess the potential of an alternative self-reporting system for adherence 
measurement. The iQS required higher participant interaction with the survey system, as 
compared with ACASI, and involved the use, customization, and interaction with a user-
designed avatar. This analysis compares differences in adherence reporting between iQS or 
ACASI as compared to the levels of drug detected in blood, and examines the predictors of 
discrepancies between self-report (iQS and ACASI) and biomarker methods of adherence 
reporting. This study was nested within ATN-110/ATN-113, in order to examine discrepancy 
in adherence reporting in greater detail. This research is crucial to examine the validity and 
explore potential correlates of discrepancies between self-reported and biomarker-reported 
PrEP adherence among YMSM at high risk for HIV acquisition.
METHODS
The NICHD-funded Adolescent Medicine Trials Network (ATN) conducted clinical trials of 
daily oral PrEP safety and efficacy among YMSM in 16 urban sites in the U.S. (ATN-110 
and ATN-113). Participants at 12 of the 16 sites were offered enrollment in a sub-study 
evaluating iQS, entitled “Structural and Partnership Factors Affecting Adherence to Pre-
Exposure Prophylaxis (PrEP) among Young Men who have Sex with Men” (ATN-123). The 
12 participating sites were located in Baltimore, Boston, Chicago, Denver, Detroit, Houston, 
Los Angeles, Memphis, Miami, New Orleans, Philadelphia, and Tampa. On or prior to their 
ATN-110/ATN-113 week 24 visit, participants were offered participation in ATN-123. 
ATN-123 began recruiting participants in July 2013, and completed enrollment in July 2015 
with 167 participants. All enrollees in ATN-123 were given the option of taking the iQS at 
the study site, on a personal mobile device, or on a personal computer. This was 
operationalized slightly differently across sites, as there were some barriers to confirming 
study activity enrollment for those who selected out of study site options. All participants 
were compensated $10–$45 for completing each iQS – compensation amount was 
determined by each site according to its research standards. Signed informed consent was 
obtained from all ATN-123 participants prior to any study activities. Participants consented 
to completing iQS questionnaires upon enrollment in ATN-123. Individuals enrolled in 
ATN-123 had previously consented to providing dried blood spot (DBS) samples and 
completing ACASI questionnaires through their participation in ATN-110/ATN-113. The 
study protocol was reviewed and approved by the IRBs at each study site and the UCLA 
IRB.
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The iQS was completed at two timepoints – timepoint one corresponded to ATN-123 
baseline, when iQS was first introduced to participants; timepoint two occurred 24 weeks 
after timepoint one, and marked the conclusion of ATN-123. The baseline of iQS 
corresponds to ACASI week 24, while the second timepoint of iQS corresponds to ACASI 
week 48; participants who enrolled in ATN-123 were first introduced to PrEP 24 weeks prior 
to ATN-123’s baseline. Questions regarding PrEP adherence asked in iQS were identical to 
those asked in ACASI. For both self-report methods, individuals were presented with a 
calendar representing the previous month, and were prompted: “This calendar represents the 
past month. Now please fill in the days you took your study pill…”
Those subjects with missing DBS data at timepoints one or two had DBS data imputed from 
a previous clinic visit no more than 12 weeks prior to the corresponding ATN-123 site visit, 
as not all participants gave DBS samples on the same dates that iQS self-interviews were 
administered (Table I). Subjects with no DBS data available for up to the 12 weeks prior to 
ATN-123 baseline or ATN-123’s conclusion at week 24 were excluded from analyses. Those 
participants missing adherence data on self-report and/or DBS were determined via 
regression analyses to not be significantly different from participants included in full 
analyses with regards to age, race, study site, heavy alcohol use in the past month, any non-
marijuana drug use in the past month, socioeconomic status, or any other relevant covariate. 
We thus expect that excluding subjects with missing adherence data from analyses will not 
induce bias.
Proportions of participants with adequate PrEP adherence were reported for all three 
adherence measurement methods – DBS, ACASI, and iQS – by timepoint. Participants were 
considered “adequately adherent” if they took PrEP at least four times a week – reflected in 
ACASI/iQS as self-reported drug-taking at least four times a week for the previous 30 days, 
and by DBS drug levels of 700fmol/punch or greater (20). In order to determine whether 
differences in proportions of subjects with adequate adherence exist between iQS, ACASI, 
and DBS, and across timepoints, McNemar’s Test, a test of marginal homogeneity, was 
utilized. McNemar’s Test was performed to compare iQS vs. ACASI, iQS vs. DBS, and 
ACASI vs. DBS at timepoints one and two. This test was selected to determine whether 
there existed discrepancies between reported adequate adherence between the three 
measurement methods, by timepoint. Frequencies and percentages of participants reporting 
preference of adherence measurement method were also tallied at each timepoint.
Crude and adjusted mixed logistic regression models with random intercept were utilized to 
determine which covariates were associated with over-reporting of medication adherence in 
self-report, while adjusting for clustering induced by having repeated measures on subjects 
across the two time points. For these regression analyses, ACASI was utilized as the self-
report measure in logistic regression analyses, as adherence measures between ACASI and 
iQS were not significantly different – as confirmed by McNemar’s Test (Table III) – and 
ACASI adherence data was more complete than was iQS data (Table I). Study participants 
were classified as over-reporting adherence if they self-reported taking PrEP at least four 
days a week, but their DBS data revealed TFV levels of less than 700 fmol/punch, the 
minimum drug level expected among individuals taking PrEP four days a week (20). 
Variables included in bivariate crude regression models included: age; race; been drunk in 
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the past month; taken any non-marijuana recreational drugs in the past month; number of sex 
partners in the past three months; currently in school; currently living with parents; ever 
received public assistance; and sexual identity. Variables included in adjusted regression 
model included: age; race; currently living with parents; been drunk in the past month; and 
ever received public assistance. Variables for inclusion in the adjusted model were selected 
based on the 10% change in effect estimate criterion. This method of variable selection has 
been shown to produce more reliable models than variable selection that is based solely on 
statistical significance of covariates (21). All analyses were performed using SAS 9.4.
RESULTS
All 167 participants enrolled in ATN-123 with non-missing self-reported and DBS-
determined data at timepoint one were YMSM, per enrollment criteria for ATN-110 or 
ATN-113, with a median age of 20 years (range of 15 to 23 years). Table II describes 
characteristics of participants overall and by over-reporting of adherence status, comparing 
adherence measured by ACASI to adherence confirmed by DBS, at timepoints one and two. 
While close to half of the participants were older YMSM, aged 21–23, about 40% were ages 
18–20, and 12% were ages 15–17. It is apparent that younger participants tended to over-
report more frequently than the older YMSM in this sample. The majority of study 
participants self-identified as gay, while about 18% were bisexual, and the remainder had 
some other sexual identity. Most study participants were African-American (55.8%), 
followed by non-Hispanic White (17.6%), Hispanic (15.2%), and other (11.5%). Participants 
had a range of education levels, although the majority had a high school diploma or less, 
which is unsurprising considering the young age of the study population. Just over half of 
ATN-123 participants had received some type of public assistance in the past, whether it be 
food stamps, social security, medical benefits, free school lunches, or other public aid. A 
fairly high proportion (75.8%) reported being drunk in the past month, and 21.8% reported 
any non-marijuana drug use in the past month. Participants most commonly had 1 or 2 sex 
partners in the past 3 months, while 13.9% did not report any sex partners in the past 3 
months, and 36.7% reported 3 or more partners.
The proportion of participants achieving adequate adherence varied by adherence 
measurement method, with DBS data recording a lower percentage of adherent participants 
than either self-report method (Table III; Figure 1). This discrepancy in proportion of 
adequately adherent individuals between self-report and biomarker data was apparent at both 
timepoints. A relatively large proportion of participants reported adequate adherence via iQS 
and ACASI at both timepoints (Figure 1; 86.6% adherent at iQS timepoint one; 82.6 % 
adherent at ACASI timepoint one; declining to 69.3 % adherent at iQS timepoint two and 
74.1% adherent at ACASI timepoint two), but DBS-estimated adherence was considerably 
lower than self-reported data. According to DBS, only 45.9% of participants were 
adequately adherent at timepoint one, decreasing to 38.8% at timepoint two. While iQS, 
ACASI, and DBS all revealed declining adherence over time, the extent of mismatch in 
adequate adherence between self-report and biomarker remained relatively large.
The results of McNemar’s test revealed that at timepoints one and two, for comparisons both 
between iQS and DBS, and between ACASI and DBS, adherence levels were not 
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homogenous (p-values <0.001; Table III). Such results provide evidence that adequate 
adherence levels are significantly different when measured by self-report vs. by biomarker. 
However, homogeneity between measures could not be rejected when comparing the two 
self-report measures (iQS vs. ACASI) at both timepoints one and two. iQS and ACASI may 
thus be expected to provide similar data on adherence.
When comparing similarity between measurement methods between timepoints, adherence 
measurements revealed that for all three methods, adherence appeared to decline over time 
(Figure 1). As determined by DBS data, 43 participants maintained adequate adherence 
across timepoints, 50 maintained inadequate adherence across timepoints, 20 participants 
had adequate adherence at timepoint one but dropped to inadequate adherence at timepoint 
2, while 8 participants had inadequate adherence at timepoint one but improved to adequate 
adherence at timepoint 2.
Over-reporting of adherence via ACASI self-report, as compared with DBS, was fairly 
common, occurring in 37.1% (59 out of 159) and 40.2% (45 out of 112) participants at 
timepoints one and two respectively. The discrepancies reported between self-reported and 
biomarker-determined data were almost entirely due to participants over-reporting their 
adherence in self-report, as compared to their DBS-determined drug levels. There was only 
one instance of an individual with adequate adherence as confirmed by DBS underreporting 
his adherence status in ACASI, and only three instances of individuals with adequate 
adherence by DBS underreporting their adherence statuses in iQS.
When asked about their preferred method of self-report for measuring their adherence to 
PrEP, at iQS baseline the majority of participants reported preference of ACASI over iQS. 
While preference of ACASI over iQS persisted at iQS week 24/ACASI week 48, the 
difference in percentage of participants preferring ACASI over iQS declined. At timepoint 
one, 68.5% (74 out of 108) participants preferred ACASI over iQS. This dropped to 58.9% 
(43 out of 73) preferring ACASI over iQS at timepoint two.
Crude mixed logistic regression random intercept models estimating the odds of over-
reporting adherence via self-report indicated that, without controlling for any other 
variables, age, race, and living with parents were significant predictors of over-reporting 
adherence in ACASI (Table IV). For each one year increase in age, without controlling for 
any other variables, participants had 0.76 times the odds of over-reporting, as compared to 
those participants one year younger, indicating that as age increases, the odds of over-
reporting decreases (95% CI: 0.65, 0.90; p-value=0.001). In the crude model, African 
American participants had 3.21 times greater odds of over-reporting, as compared to non-
African American participants (95% CI: 1.69, 6.08; p-value=0.0004). Living with parents 
was also associated with over-reporting adherence in the crude mixed model; those YMSM 
who lived with their parents had 2.72 times greater odds of over-reporting adherence, as 
compared with YMSM who did not live with their parents (95% CI: 1.47, 5.01; p-
value=0.002). No other covariates revealed significant associations with over-reporting 
status in the crude models.
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The adjusted mixed logistic regression random intercept model indicated that, after 
controlling for all other variables in the model (age; race; living with parents vs. not living 
with parents; any binge alcohol drinking in the past month; and ever received public 
assistance), both age and race remained significantly associated with over-reporting, while 
living with parents was trending towards significance (Table IV). All else equal, each one 
year increase in age was associated with 0.79 times the odds of over-reporting PrEP 
adherence, indicating that as age increases, odds of over-reporting decreases (95% CI: 0.63, 
0.98; p-value=0.031). All else equal, African-Americans had 3.22 times higher odds of over-
reporting adherence status than non-African Americans (95% CI: 1.51, 6.90; p-
value=0.003). While living with parents had a p-value marginally greater than 0.05 (p-
value=0.058), it appears that living with parents may also be positively associated with over-
reporting adherence, after adjusting for other covariates (OR = 2.13; 95% CI: 0.97, 4.66).
DISCUSSION
These findings confirm large discrepancies in adherence reporting between self-reported 
(both ACASI and iQS) and biomarker-identified levels of use of pre-exposure prophylaxis 
among young men who have sex with men across multiple cities in the U.S. In the setting of 
a clinical trial, a different approach to collecting self-reported data (i.e. iQS) did not improve 
the accuracy of such reports, and collection of adherence data revealed a higher proportion 
of incomplete data for adherence measured when collected via iQS vs. ACASI. Adherence 
reports were similar between the two methods of self-report at both timepoints; 
discrepancies between PrEP adherence measured in ACASI and iQS compared to blood 
drug levels suggest substantial over-reporting of adherence through these subjective 
methods. DBS, ACASI, and iQS-reported adherence levels all decreased over time, but self-
reported data revealed large over-estimations of DBS-estimated adherence levels; 
approximately 40% of individuals self-reporting adequate adherence at both timepoints over-
reported their adherence, as estimated by DBS (Figure 1), emphasizing the need for 
biomarkers to accurately assess adherence.
Of note, the YMSM in this study generally tended to prefer ACASI over iQS, which may be 
because all participants in ATN-123 had previous experience with ACASI in the parent 
study (ATN-110/113) prior to their enrollment in ATN-123. Participants may have preferred 
ACASI over iQS simply due to their familiarity with ACASI. Supporting this possibility is 
that the percentage of participants preferring iQS increased by timepoint two. Thus, 
participants may have preferred iQS after they gained more familiarity in this method of 
self-report. In future studies, participants should have equal experience with each method in 
order to get a more accurate measurement of self-report measure preference.
Our finding that younger age was associated with discrepancies in adherence reporting may 
be due to a variety of factors. Firstly, adolescent boys may be more concerned about getting 
in “trouble” with researchers if they report poor adherence to PrEP, while young men in the 
study may be more aware that they will not get in trouble if they report low adherence levels. 
Age may also be associated with tendency to over-report, and adolescence may be a period 
associated with a time of particular vulnerability to adhere to social norms, such as 
medication adherence (22). Furthermore, adolescents may face heightened susceptibility to 
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social desirability bias, and younger individuals may thus provide answers that conform with 
what they expect would be deemed acceptable by the researchers (23). These findings 
suggest that younger study participants should be encouraged that their answers to any 
questions on self-interview will be confidential, that truthful answers are most helpful to 
researchers, and that they will not face negative consequences from the research team for 
their answers.
Despite the fact that living with parents failed to reach statistical significance in the adjusted 
model, it is possible that living with parents is a relevant factor that acts as a barrier for 
YMSM to properly report their PrEP use. YMSM living with parents may not wish to 
disclose their sexual orientation, sexual activity, and/or their PrEP use to their parents, and 
may be similarly uncomfortable disclosing PrEP use concerns to researchers. Additionally, if 
YMSM are with their parents at the time they are scheduled to take their daily PrEP dose, 
their ability to adhere may be hindered, and PrEP use associated with a need to act covertly. 
It was noted in iPrEx’s qualitative study that as PrEP has a distinctive appearance, some 
MSM in the study said that carrying PrEP attracted unwanted attention from others (24). 
Researchers should be aware that being able to discreetly take and discuss PrEP may be 
important for MSM in general, and may be particularly crucial for YMSM who live in 
households with their parents.
The fact that race, and particular that being African American, was significantly associated 
with over-reporting is particularly concerning, as this population group is the most 
vulnerable to HIV acquisition in the U.S. (4,5). The need to understand barriers that prevent 
African American YMSM from being able to adhere to PrEP is thus crucial. Findings from 
this study indicate that barriers currently exist that prevent African American YMSM from 
being able to disclose personal and sensitive information to researchers. It is possible that 
health researchers are currently insufficiently able establish rapport with young African 
American males, which leads to a lack of trust between the researcher and participant. 
Previous studies have found that African American boys and young men, and particularly 
African American YMSM, may be more likely than their non-African American 
counterparts to distrust or be wary of medical professionals (25–27). This distrust is rooted 
in historical fact, as 400 African American men in the Tuskegee Syphilis study were 
unethically and inhumanely denied treatment from 1932 to 1972 (25). Although eliminating 
such distrust will be difficult, there are ways in which African American YMSM can be 
encouraged to trust health research, like PrEP studies, from which they may benefit. For 
example, having a greater number of young African American males on research teams, and 
as physicians, nurses, and other clinicians at clinic sites, may allow young African American 
men to feel greater comfort, trust, and encouragement to participate in health research. 
Current health professionals should also receive further training in cultural competence in 
order to improve researcher-participant and provider-patient interactions, communications, 
trust, and understanding (25).
Age, race, and, potentially, living with parents are associated not only with over-reporting of 
PrEP adherence, but also with poor DBS-estimated PrEP adherence. Young, African 
American MSM who live with their parents are less likely to accurately self-report their 
PrEP adherence, and less likely to properly adhere to PrEP, as compared to older, non-
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African American YMSM who do not live with their parents. This suggests that these 
individuals would benefit from support to encourage both daily PrEP-taking and accurate 
self-reporting even when adherence is low.
This study relies on the assumption that DBS is a valid method of measuring PrEP for 
individuals enrolled in ATN-123. While DBS is generally considered to be an accurate, 
valid, and accepted method of determining PrEP adherence (28,29), the performance of DBS 
as a measure of PrEP adherence across different age and racial groups continues to be 
assessed.
LIMITATIONS
ATN-123 faced some notable limitations. Firstly, although compensation amounts were 
determined prior to study initiation, in practice there were variations in compensation 
amounts given to participants across study sites. Although lower compensation for certain 
participants did not negatively impacted study retention rates for iQS, it may have reduced 
enthusiasm for the method. It may have been perceived as more burdensome because the 
compensation for participating in the sub-study was as low as $10 in some sites, which may 
have been inadequate for the participants’ time, but up to $45 in others, though participants 
were not aware of the compensation discrepancies. Additionally, a 30-day recall of 
medication adherence was utilized, which may pose difficulty for accurate reporting of 
medication-taking . Future studies could utilize less burdensome recall periods to asses if 
that improves reporting. Thirty day recall, however, has previously been demonstrated as 
having lower rates of over-reporting of HIV medication adherence, as compared with three 
day or seven day recall (30). An additional limitation was the operationalization of the iQS. 
The prototype avatar was conceptualized as realistic, customizable, interactive, and visually 
appealing. In practice, however, due to technological limitations, the avatar was a simplified, 
juvenile cartoon figure with minimal customization options and only minimally interactive. 
To assess the potential for an interactive mode to improve adherence, future studies will 
need avatars that are more like virtual humans and more appealing. This study also 
experienced loss to follow up, which resulted in a loss of sample size and the potential that 
those participants who were lost may have faced different barriers to PrEP adherence than 
participants who were retained in the study. Although loss to follow up was not found to be 
associated with PrEP adherence or other measured covariates, losing participants affected 
sample size, which may have impacted statistical efficiency. The reasons for loss to follow 
up, especially for iQS, must be explored in more depth.
CONCLUSION
The results of ATN-123 provide further evidence that self-report methods of adherence to 
PrEP in clinical trials suffer from considerable over-reporting and likely do not accurately 
capture true levels of medication adherence. Discrepancies between self-reported and 
biomarker-determined PrEP adherence are not uniform across participants, however, and 
individuals who are younger, African American, and possibly those who live with their 
parents may be more likely to over-report medication adherence, as compared to older, non-
African American individuals who do not live with their partners. These findings indicate 
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that young, African American YMSM individuals may feel uncomfortable disclosing 
concerns regarding PrEP use, and that mistrust of health professionals and social desirability 
bias may impact PrEP use reporting among this population.
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Figure 1. 
Changes in percentage of participants with adequate PrEP adherence from timepoint 1 to 
timepoint 2, by adherence measurement method
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Table I
Number of participants with non-missing vs. fully-missing adherence data by data collection method and 
timepoint.
Timepoint 1 Timepoint 2
Data collection
method
Number
non-missing
Number missing
adherence data
Number non-
missing
Number missing
adherence data
ACASI 167 0 135 32
iQS (n=137) 123 14 86 51
DBS (n=167) 159* 8 121* 38
*Since participants didn't always give DBS samples at timepoints that exactly corresponded with ACASI and iQS administration dates, DBS data 
from up to the previous 12 weeks were imputed for timepoints 1 and 2. For timepoint 1, 20 participants had DBS imputed from up to 12 weeks 
prior to ACASI/iQS timepoint 1; for timepoint 2, 24 participants had DBS imputed from up to 12 weeks prior to ACASI/iQS timepoint 2.
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